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Summary 
 
Although recent clinical trials of BRAF inhibitor combinations have demonstrated 
improved efficacy in BRAF mutant colorectal cancer, emergence of acquired 
resistance limits clinical benefit. Here, we undertook a comprehensive effort to define 
mechanisms underlying drug resistance with the goal of guiding development of 
therapeutic strategies to overcome this limitation. We generated a broad panel of 
BRAF mutant resistant cell line models across seven different clinically-relevant drug 
combinations. Combinatorial drug treatments were able to abrogate ERK1/2 
phosphorylation in parental sensitive cells, but not in their resistant counterparts, 
indicating that resistant cells escaped drug treatments through one or more 
mechanisms leading to biochemical reactivation of the MAPK signaling pathway. 
Genotyping of resistant cells identified gene amplification of EGFR, KRAS and 
mutant BRAF, as well as acquired mutations in KRAS, EGFR, and MAP2K1. These 
mechanisms were clinically relevant, as we identified emergence of a KRAS G12C 
mutation and increase of mutant BRAF V600E allele frequency in the circulating 
tumor DNA of a patient at relapse from combined treatment with BRAF and MEK 
inhibitors. In order to identify therapeutic combinations capable of overcoming drug 
resistance, we performed a systematic assessment of candidate therapies across 
the panel of resistant cell lines. Independent of the molecular alteration acquired 
upon drug pressure, most resistant cells retained sensitivity to vertical MAPK 
pathway suppression when combinations of ERK, BRAF, and EGFR inhibitors were 
applied. These therapeutic combinations represent promising strategies for future 
clinical trials in BRAF mutant colorectal cancer. 
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INTRODUCTION 
 
Activating mutations in the BRAF oncogene occur in approximately 7% of human 
malignancies, including 50-60% of melanomas and 5-8% of colorectal cancers 
(CRCs) (1). The most frequent BRAF mutation (V600E) affects the kinase domain, 
mimics BRAF phosphorylated state, and leads to constitutive activation of the protein 
(1). In CRC, BRAF mutations are associated with hypermethylated tumor subtypes 
and are linked with aggressive, less-differentiated and therapy-resistant disease (2). 
Metastatic CRC (mCRC) patients with BRAF V600E mutant tumors show poor 
sensitivity to the EGFR-targeted monoclonal antibodies panitumumab and cetuximab 
and display poor prognosis with a median overall survival of only about 6-9 months 
(3). 
 
BRAF V600E mutant tumor types do not respond uniformly to BRAF-targeted 
therapy (4). Targeted inhibitors of mutant BRAF alone, or in combination with 
inhibitors of its downstream effector MEK, induce high response rates in BRAF 
mutant melanoma (5,6); by contrast, a phase I study of mCRC patients has shown 
that the BRAF inhibitor (BRAFi) vemurafenib has no clinical benefit when given as 
monotherapy (7). The molecular basis of this discrepancy has been partly explained 
by dissimilar EGFR expression levels between these two malignancies. Intrinsic 
resistance of CRC cells to BRAF or MEK targeted agents is mediated by the release 
of a feedback loop which activates EGFR signaling, leading to reactivation of MAPK 
signaling and often to upregulation of parallel PI3K-AKT pathways, triggering 
proliferation and survival (8-10). Melanomas are sensitive to BRAFi as they originate 
from the neural crest and do not express EGFR, making this feedback loop 
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ineffective. On the other hand, CRCs arise from epithelial cells in which EGFR is 
generally constitutively expressed.  
 
These preclinical studies have provided the rationale for testing dual/triple vertical 
blockade of the MAPK pathway by targeting EGFR, BRAF, and MEK in BRAF 
mutant mCRC patients. Combinations targeting EGFR, BRAF, and the pro-survival 
PI3K pathways are also being explored. Clinical objective responses have been 
seen in 20-40% of patients treated with doublet or triplet combinatorial regimens (11-
13).  
 
Nevertheless, preliminary clinical evidence from phase Ib trials shows that responses 
are limited in duration (4,11-16). The molecular basis underlying intrinsic or acquired 
resistance to these drug combinations in BRAF mutant mCRC has not been 
comprehensively defined. The mechanisms by which cancer cells evade targeted 
therapies are usually molecularly heterogeneous, but they often converge 
downstream in the pathway which was originally blocked by the targeted agent. For 
instance, cell lines and mCRC patients that become resistant to single-agent 
cetuximab or panitumumab show a variety of molecular mechanisms that converge 
in reactivating the MAPK pathway, including mutations in the drug binding sites of 
EGFR, RAS/RAF amplification or mutations, or genetic alterations leading to 
activation of alternative receptor tyrosine kinases (RTKs) such as MET or HER2 
(reviewed in (17)). Similarly, BRAF mutant melanomas that become refractory to 
BRAF and/or MEK inhibitors (MEKi) also show a variety of molecular mechanisms 
leading to reactivation of MAPK and/or AKT signaling. These include increased 
expression of RTKs such as PDGFRβ, IGF-1R and EGFR; overexpression of the 
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COT kinase; mutation of MEK1 (MAP2K1) and MEK2 (MAP2K2) kinase; MITF or 
NRAS mutations; amplification, or alternative splicing of the BRAF gene; CDKN2A 
loss; or genetic alterations in the PI3K-PTEN-AKT pathway (reviewed in (18)). 
 
On these premises, we hypothesized that heterogeneous genetic alterations leading 
to reactivation of the MAPK pathway could be responsible for acquired resistance to 
regimens co-targeting EGFR, BRAF, MEK, and PI3K in CRC patients, despite 
vertical pathway suppression at multiple key nodes. To perform a comprehensive 
assessment of the landscape of potential acquired resistance mechanisms, we 
cultured BRAF mutant CRC cell lines in the presence of seven distinct clinically-
relevant combinatorial regimens until the emergence of resistant derivatives. These 
cell lines were subjected to genetic, biochemical, and functional analyses to identify 
molecular alterations underlying drug resistance. Since in vitro modeling of acquired 
resistance in cancer cell models has proven effective in identifying resistance 
mechanisms that occur clinically (19-21), these findings may predict those 
mechanisms of resistance likely to arise in patients. These preclinical models also 
represent valuable tools for key functional studies aimed at identifying effective 
strategies to overcome drug resistance.  
 
 
Materials and Methods 
 
Generation of drug resistant cell lines 
WiDr parental cells were a gift from Dr René Bernards (Amsterdam, The 
Netherlands) in July 2011. HROC87 parental cells were shared by Michael 
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Linnebacher (Rostock, Germany) in September 2011. VACO432 parental cells were 
obtained from Horizon Discovery (Cambridge, United Kingdom) in March 2011. The 
genetic identity of parental cell lines and their resistant derivatives was confirmed by 
short tandem repeat profiling (Cell ID System; Promega) not fewer than 2 months 
before drug profiling experiments. BRAF mutant HROC87, VACO432 and WiDr cells 
were seeded in 100-mm dishes at a density of 5x106/plate and treated with drug 
combinations as indicated in Supplementary Table S1. Additional information is 
provided in Supplementary Materials and Methods. 
 
Drug sensitivity assay 
Cell proliferation and cytoxicity were determined by cellular ATP levels (CellTiter-Glo 
Luminescent Assay; Promega) and DNA incorporation of a fluorescent cyanine dye 
(CellTox Green; Promega) after 72 hours’ drug treatment, respectively. Additional 
information is provided in Supplementary Materials and Methods and 
Supplementary Table S2.  
 
Western Blot analysis  
Protein quantification, SDS-PAGE, western blotting and chemiluminescent detection 
were performed as previously described (19). Detailed information is provided in 
Supplementary Materials and Methods. 
 
Gene copy number analysis qPCR 
Cell line DNA (10 ng) was amplified by quantitative PCR using the GoTaq QPCR 
Master Mix (Promega) with an ABI PRISM 7900HT apparatus (Applied Biosytems). 
HER2, MET, EGFR, KRAS and BRAF gene copy number was assessed as 
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previously described (19). Data were normalized to a control diploid cell line, HCEC 
(22) and expressed as the ratio between resistant and the corresponding parental 
cells. Primer sequences are reported in Supplementary Table S3. 
 
 
Fluorescence In Situ Hybridization (FISH) 
Dual color FISH analysis was performed using: Chr7q (7q11.21) / BRAF (7q34) 
probes; Chr7q / EGFR (7p12) probes; Chr12q (12q12) / KRAS (12p12.1) probes 
(Abnova); all probe pairs labelled with FITC and Texas Red, respectively. Details are 
provided in Supplementary Materials and Methods. 
 
Candidate-gene mutational analysis  
Cell line DNA was extracted by Wizard® SV Genomic DNA Purification System 
(Promega) according to manufacturer’s directions. The following genes and exons 
were analyzed by automated Sanger sequencing by ABI PRISM 3730 (Applied 
Biosystems): KRAS (exons 2, 3 and 4), NRAS (exons 2 and 3), BRAF (exon 15), 
EGFR (exon12), MAP2K1 (exons 2 and 3), MAP2K2 (exon 2). Primer sequences are 
listed in Supplementary Table S3. 
 
Droplet Digital PCR (ddPCR) 
Genomic DNA from CRC cells was amplified using ddPCR™ Supermix for Probes 
(Bio-Rad) using BRAF V600E assay (PrimePCR™ ddPCR™ Mutation Assay, Bio-
Rad). ddPCR was then performed according to manufacturer’s protocol and the 
results reported as percentage or fractional abundance of mutant DNA alleles to total 
(mutant plus wild type) DNA alleles, as previously described (23).  
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Viral Infection 
The lentivirus production, cell infection, and transduction procedures were performed 
as previously described (24). WiDr cells were transduced with a lenti-control vector 
or a lentiviral vector carrying a mutated hBRAF V600E cDNA (a gift of Maria S. 
Soengas, CNIO, Madrid, Spain) or EGFR WT cDNA (a gift from Dr. C. Sun and Prof 
R. Bernards, NKI, Amsterdam). VACO432 cells were transduced with a lentiviral 
vector carrying EGFR G465R mutant cDNA (25).  
 
Clinical samples 
A chemorefractory metastatic CRC patient was enrolled in the CMEK162X2110 
clinical trial (Trial registration ID: NCT01543698) at Niguarda Cancer Center, Milan, 
Italy. The patient was treated with the BRAFi encorafenib (LGX818) in combination 
with the MEKi binimetinib (MEK162) from September 2013 to March 2014, obtaining 
a partial response in January 2014, followed by radiological progression in March 
2014. Blood samples from this patient were obtained at baseline (September 2013) 
and at progression (March 2014) through a separate liquid biopsy research protocol 
approved by the Ethics Committee at Ospedale Niguarda, Milan, Italy. The study 
was conducted according to the provisions of the Declaration of Helsinki, and the 
patient signed and provided informed consent before sample collection.  
 
Next Generation Sequencing (NGS) analysis 
Germline DNA was obtained from PBMC (Promega, ReliaPrep Tissue Kit), while cell 
free circulating DNA of tumor origin (ctDNA) was extracted from 2 ml plasma using 
the QIAamp Circulating Nucleic Acid Kit (Qiagen) according to the manufacturer's 
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instructions. Libraries were prepared with Nextera Rapid Capture Custom 
Enrichment Kit (Illumina Inc., San Diego, CA, USA), according to the manufacturer’s 
protocol, as previously described (23). The custom-panel included the coding region 
of 226 genes, as previously detailed (23). Further details are provided in 
Supplementary Materials and Methods. 
 
Bioinformatics analysis  
NGS bioinformatics analysis was performed as previously described (23). Mutational 
analyses were the result of comparison between pre- and post-treatment samples. 
Details are provided in Supplementary Materials and Methods. 
  
Results 
 
Generation of models of acquired resistance to combinatorial therapies 
targeting EGFR-BRAF-MEK-PI3K 
We selected three BRAF V600E mutant CRC cell lines, HROC87, WiDr and 
VACO432, that are resistant to single-agent BRAFi or MEKi, but sensitive to 
combined BRAFi/MEKi or their combinations with cetuximab (Supplementary Fig. 
S1). To gain a comprehensive understanding of potential therapeutic resistance 
mechanisms in BRAF mutant CRC, cell lines were cultured until resistant derivatives 
emerged in the presence of seven different drug combinations currently being 
explored in clinical trials. The drugs included the BRAFi dabrafenib, encorafenib, and 
vemurafenib; the MEKi selumetinib and trametinib; the EGFR-targeted antibody 
cetuximab; and the selective PI3K-α inhibitor (PI3Ki) alpelisib (Fig. 1A). A total of 
eleven resistant cell line models were generated. Two independent resistant cell 
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populations were obtained by growing VACO432 cells with vemurafenib and 
cetuximab (V+C) and these were therefore indicated as resistant A (R.A) and 
resistant B (R.B). Resistance to drug treatment was confirmed by cell viability assay 
comparing parental and resistant cell derivatives. All resistant cell models were 
clearly refractory at all drug concentrations tested (Fig. 1B).  
 
Cells with acquired resistance to BRAF inhibitor combinations display 
biochemical reactivation of MAPK signaling 
Prior studies indicate that tumors with acquired resistance to BRAF or EGFR 
targeted agents in monotherapy maintain sustained levels of MEK/ERK or 
(occasionally) AKT phosphorylation even in the presence of drug (19,26-29). We 
tested whether the same biochemical rewiring could occur in cells made resistant to 
combinations of therapies targeting EGFR-BRAF-MEK-PI3K. Amounts of total MEK, 
ERK, or AKT proteins were not substantially different between parental cells and 
their resistant counterparts. However, variation of their phosphorylation levels 
(pMEK, pERK, or pAKT) was evident after drug treatment. Some, but not all, 
resistant models displayed increased phosphorylation of AKT at Ser473 upon drug 
treatment. However, every resistant model showed sustained levels of ERK 
phosphorylation despite drug treatment, in stark contrast to parental cells in which 
robust inhibition of ERK phosphorylation was observed with all treatments (Fig. 2).  
 
Overall, these analyses indicate that combinatorial EGFRi/BRAFi/MEKi/PI3Ki 
treatments abrogate ERK phosphorylation in parental sensitive cells, but that their 
resistant counterparts can sustain MAPK signaling in the presence of these 
therapeutic combinations (Fig. 2).  
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Acquired molecular alterations in BRAF mutant CRC cell lines confer 
resistance to BRAF inhibitor combinations 
In order to identify likely candidate drug resistance mechanisms leading to 
biochemical reactivation of MAPK signaling, we focused our analysis on components 
of the MAPK pathway by performing copy-number analyses of HER2, EGFR, MET, 
KRAS and BRAF and Sanger sequencing of the most pertinent exons of EGFR, 
KRAS, NRAS, BRAF, MAP2K2 and MAP2K1.  
 
Quantitative PCR on genomic DNA extracted from resistant cells showed no 
changes in HER2 or MET gene copy number while EGFR, KRAS, or BRAF gene 
copy number increased in three WiDr derivatives resistant to V+S, D+C or S+C, 
respectively (Fig. 3A). All gene amplifications were only found in the resistant cell 
populations and were confirmed by fluorescence in situ hybridization (FISH) 
analyses (Fig. 3B). Sanger sequencing of hotspot regions of EGFR (exon 12), KRAS 
(exons 2, 3, and 4), NRAS (exons 2 and 3), BRAF (exon 15), MAP2K1 (exons 2 and 
3) and MAP2K2 (exon 2) revealed acquired gene mutations in eight cell lines, as 
summarized in Table 1. All resistant cell populations retained the original BRAF 
V600E mutation. All other mutations found in resistant cells were not detected in 
their parental counterparts by conventional Sanger sequencing. 
 
Alterations in KRAS were the most common resistance mechanisms observed. 
Acquired KRAS mutations affecting exons 2 and 4 (G12D, G13D and A146T/V) were 
found in five different cell line models resistant to doublet BRAFi+EGFRi or triplet 
E+C+A. In one case, multiple KRAS mutations were concomitantly present in the 
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resistant cell population, suggesting polyclonality. Prior functional studies in cell 
models have already demonstrated a causative role of exon 2 KRAS mutations in 
driving resistance to BRAFi+EGFRi (30). Our data suggest that exon 4 KRAS 
mutations can also promote resistance. Additionally, KRAS amplification was 
identified in WiDr resistant to BRAFi+EGFRi (D+C). KRAS amplification was found in 
the post-treatment biopsy of a CRC patient with acquired resistance to the 
combination of encorafenib and cetuximab (30). These findings suggest that the cell 
models generated in this work have the potential to recapitulate clinically-relevant 
resistance mechanisms.  
 
Increased BRAF gene copy number was seen in WiDr resistant to MEKi+EGFRi 
(S+C). Selective amplification of mutant BRAF V600E allele was previously identified 
in a BRAF mutant CRC patient with acquired resistance to BRAFi+EGFRi (30), in 
CRC cell lines with secondary resistance to the MEKi selumetinib (31,32), as well as 
in melanoma patients upon progression on the BRAFi vemurafenib (33), but not yet 
implicated in refractoriness to combined MEKi+EGFRi. To assess whether BRAF 
gene amplification had occurred in an allele selective manner, we performed digital 
PCR analyses. WiDr parental cells carried 1 mutant and 3 wild-type alleles of BRAF, 
while their S+C resistant derivatives displayed a 9:1 mutant/wildtype ratio 
(Supplementary Fig. S2A). Western blot with a diagnostic antibody specific for the 
V600E variant showed that the mutant protein was selectively overexpressed 
(Supplementary Fig. S2B). Finally, we validated that ectopic overexpression of 
mutant BRAF in WiDr parental cells can confer resistance to combined MEKi+EGFRi 
(Supplementary Fig. S2C and S2D).  
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Two different MAP2K1 mutations leading to the V211D and L115P amino acid 
changes were identified in HROC87 and VACO432 resistant to MEKi+EGFRi (S+C) 
and BRAFi+MEKi (D+T), respectively. These mutations have previously been 
reported to confer resistance to MEK allosteric inhibitors in melanoma and CRC by 
preventing drug binding (27,34), so they were not subjected to further functional 
validation. 
 
Interestingly, amplification of EGFR was found in WiDr resistant to BRAFi+MEKi 
(V+S). Although EGFR signaling has been implicated in intrinsic resistance to BRAFi 
monotherapy in BRAF mutant CRC (8,9), EGFR gene amplification has not 
previously been established as a potential resistance mechanism in BRAF mutant 
CRC. This result is consistent with previous observations that induction of EGFR 
protein expression can drive resistance to BRAFi or MEKi in melanoma (35). Ectopic 
overexpression of EGFR in WiDr parental cells was able to confer resistance to 
combined BRAFi+MEKi or BRAFi+EGFRi (Fig. 4A and 4B). Importantly, however, 
the triple combination of BRAFi+EGFRi+MEKi was able to restore sensitivity in 
resistant cells carrying EGFR amplification (Fig. 4C).  
 
A single point mutation affecting the ectodomain of EGFR (G465R) was found in 
VACO432 V+C (R.B). Although this variant has previously been shown to disrupt 
receptor-antibody interaction, leading to cetuximab or panitumumab resistance in 
RAS/BRAF wild-type CRCs (25), mutations affecting the EGFR ectodomain have not 
been reported previously as potential resistance mechanisms in the context of BRAF 
mutant tumors. To investigate the role of this mutation, we induced ectopic 
expression of EGFR G465R in VACO432 parental cells. Analysis of transduced cells 
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indicated that the EGFR G465R mutation is able to sustain ERK phosphorylation and 
cell proliferation in the presence of combined V+C treatment (Fig. 4D and 4E). 
Cross-resistance to the combination of vemurafenib and panitumumab was seen. 
However, consistent with its known role in disrupting anti-EGFR antibody binding, 
the ability of the EGFR G465R mutation to promote resistance was specific to 
BRAFi+EGFRi combinations with anti-EGFR antibodies only, and kinase inhibition of 
EGFR by gefitinib was able to restore sensitivity in combination with BRAFi (Fig. 4F).  
 
Clinical acquired resistance to combined therapy with BRAF and MEK 
inhibitors 
Identification of clinical acquired resistance mechanisms to targeted therapy 
combinations was performed by genotyping of liquid biopsy samples. Plasma 
samples taken before treatment and after disease progression were collected from a 
patient with BRAF V600E mutant colorectal cancer who had achieved a partial 
response on a RAF/MEK inhibitor combination (Trial registration ID: NCT01543698). 
Circulating tumor DNA (ctDNA) was extracted and subjected to molecular profiling by 
NGS analysis of a custom panel of 226 cancer related genes (23). The analysis 
revealed that the percentage of reads carrying TP53 p.R282W mutated allele were 
consistent between the baseline and the progression plasma (Fig. 5), indicating 
similar ctDNA content in both samples. By contrast, the proportion of BRAF V600E 
mutant reads at resistance was twice as much as those in the baseline, suggesting 
selective amplification of the BRAF mutant allele. NGS analysis revealed 
concomitantly the emergence of a KRAS G12C allele, which was undetectable in the 
pretreatment sample. These results indicate that the mechanisms of resistance to 
18 
 
target inhibitors identified in cell lines could faithfully recapitulate those found in 
clinical samples. 
 
Overall, we observed that a diverse array of molecular mechanisms can drive 
acquired resistance to clinically-relevant therapeutic combinations targeting the 
EGFR-BRAF-MEK-PI3K pathways in BRAF mutant CRC. However, we also found 
that each of these heterogeneous resistance mechanisms converges on a common 
signaling output to promote resistance-reactivation of MAPK signaling ― suggesting 
that it may be possible to devise a universal targeted combination strategy capable 
of overcoming multiple resistance mechanisms. 
 
Vertical combined suppression of the MAPK pathway has residual activity on 
drug resistant cells 
Based on our observations that all resistant cell models show persistent MAPK 
signaling activation (Fig. 2), we postulated that they could retain sensitivity to 
suppression of the pathway downstream. In this regard, previous data indicate that 
some melanomas with acquired resistance to BRAFi monotherapy can benefit from 
additional treatment based on combined BRAFi and MEKi blockade (36). 
Additionally, vertical triple blockade of EGFR+BRAF+MEK displayed the highest 
ability to suppress ERK phosphorylation in BRAF V600E CRC cells (37) and this 
combination has been shown to induce response rates of up to 40% in BRAF mutant 
CRC patients (11). Similarly, previously published reports have documented 
promising preclinical activity of ERK inhibition in BRAFi or MEKi resistant melanoma 
models (27,38,39) as well as in MEKi+BRAFi or BRAFi+EGFRi resistant BRAF 
mutant CRC cells (30). However, it has not yet been established whether ERK 
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inhibitors might exhibit improved ability to overcome resistance when given as 
monotherapy, or in combination with BRAFi and/or EGFRi. Accordingly, we 
hypothesized that acquired resistance to BRAFi combinations could be overcome by 
more profound MAPK pathway suppression achieved by triplet combinations or by 
the incorporation of ERK inhibitor-based combinations. In order to test these 
hypotheses, the effect on viability was systematically tested across all resistant cell 
line models for all drug combinations used to generate resistant derivatives, as well 
as combinations incorporating the ERK inhibitor (ERKi) SCH772984 and the vertical 
cetuximab+dabrafenib+trametinib (BRAFi+MEKi+EGFRi) triplet combination (Fig. 6).  
 
As expected, parental cell lines were highly sensitive to all drug treatments (Fig. 6). 
In general, resistant cell lines derived from one BRAFi+MEKi combination (D+T or 
V+S) showed cross-resistance to the other BRAFi+MEKi combination; and cell lines 
resistant to cetuximab in combination with encorafenib, dabrafenib or vemurafenib 
were cross-resistant to other BRAFi+EGFRi combinations, irrespective of the specific 
drug used in the selection protocol. This suggests that resistance mechanisms 
emerging under the selective pressure of these specific drug combinations are 
capable of conferring resistance to that class of inhibitors, and are unlikely to be 
related to any unique properties of the specific drugs used.  
 
Interestingly, the addition of PI3Ki to BRAFi+EGFRi treatment did not robustly affect 
viability in any of the resistant cells relative to BRAFi+EGFRi alone. This finding is 
consistent with initial results of a clinical trial comparing encorafenib and cetuximab 
to encorafenib, cetuximab, and alpelisib, which have not demonstrated a clear 
benefit in response rate or progression-free survival with the addition of the PI3K 
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inhibitor alpelisib (12,40). In marked contrast, the triple combination of 
BRAFi+EGFRi+MEKi showed improved efficacy in many models relative to either 
BRAFi+EGFRi, BRAFi+MEKi, or MEKi+EGFRi alone. Finally, the addition of BRAFi 
and/or EGFRi to ERKi appeared to improve efficacy in some resistant models 
relative to ERKi alone, suggesting that ERKi may best be administered as part of 
therapeutic combinations in future clinical trials for BRAF mutant CRC. Indeed, 
analysis of resistant cell lines indicated that ERK inhibition could induce cytotoxicity, 
which was further enhanced when combined with BRAFi and/or EGFRi 
(Supplementary Figures 3A and 3B).   
 
 
Discussion 
Over the past few years, BRAF inhibitors have demonstrated striking clinical efficacy 
in patients with BRAF mutant melanoma. However, BRAF inhibitors are not equally 
effective in other BRAF mutant cancer histologies (4). Preclinical studies defining 
EGFR and MAPK pathway reactivation as key drivers of BRAF inhibitor resistance in 
BRAF mutant CRC have provided the rationale for testing double or triple 
combinations of therapies targeting EGFR/BRAF/MEK/PI3K in this disease (11-
13,15,16).  
 
Unfortunately, while these approaches have led to improvements in response rate in 
BRAF mutant CRC patients, preliminary clinical observations have indicated that, 
following an initial response, acquired resistance in BRAF mutant CRC patients 
typically emerges after a few months of treatment (11-13,15). The mechanisms 
underlying acquired resistance in BRAF mutant CRC cells remain poorly 
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characterized. In this study, we undertook a comprehensive effort to develop models 
of secondary resistance to a spectrum of seven clinically-relevant combinatorial 
therapies in order to more robustly define the landscape of molecular mechanisms 
leading to acquired resistance in BRAF mutant CRC. Our results indicate that the 
mechanisms leading to acquired resistance to these combinations can be genetically 
heterogeneous, but appear to converge on the reactivation of the MAPK signaling 
pathway at the biochemical level, suggesting that it might be possible to develop 
universal combination strategies capable of overcoming multiple resistance 
mechanisms. We acknowledge that no in vivo models were generated or assessed 
in this study, thus limiting our observations to cancer cell autonomous drug 
resistance mechanisms. However, analyses of plasma samples at baseline and at 
acquired resistance to BRAF combinatorial therapy, in a BRAF mutant CRC patient, 
revealed genetic alterations consistent with those identified in cell models, thus 
underscoring the clinical relevance of the broad panel of resistant lines generated in 
this work. Since microenvironment and non-genomic mechanisms of drug resistance 
may also occur, future studies based on the analysis of BRAF mutant murine models 
and patient samples will be needed to expand our knowledge on this aspect.  
 
In our resistant cell line panel, we identified several novel mechanisms of acquired 
resistance not previously reported in BRAF mutant CRC. In particular, we identified 
an EGFR G465R ectodomain mutation in a cell line with acquired resistance to the 
combination of a BRAFi and anti-EGFR antibody. While this mutation has been 
established as a mechanism of acquired resistance to anti-EGFR antibody 
monotherapy in RAS/BRAF wild-type CRC due to disruption of antibody binding (25), 
this class of mutations has not previously been implicated in BRAF mutant CRC. Our 
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observation warrants assessing for EGFR ectodomain mutations in BRAF mutant 
CRC patients upon acquired resistance to BRAFi and anti-EGFR antibody 
combinations. Importantly, we found that a resistant model harboring this mutation 
retained sensitivity to BRAFi and an EGFR kinase inhibitor, as well as to 
downstream inhibitor combinations, such as BRAFi+MEKi. We also identified EGFR 
amplification as a novel potential mechanism of acquired resistance in BRAF mutant 
CRC. Interestingly, unlike the EGFR ectodomain mutation, EGFR amplification 
conferred cross-resistance to BRAFi+EGFRi, BRAFi+MEKi, and MEKi+EGFRi 
combinations, likely as a consequence of increased EGFR signalling flux, and 
retained sensitivity only to the triple combinations of BRAFi+EGFRi+MEKi and 
ERKi+BRAFi+EGFRi. The finding that EGFR signaling leads to MAPK feedback 
reactivation and resistance during BRAFi monotherapy, but also can contribute to 
acquired resistance to MAPK combinatorial inhibition, highlights the central role of 
EGFR in the biology of BRAF mutant CRC.  
 
Molecular analyses of our resistance cell line panel also identified the presence of 
several resistance mechanisms previously identified in the setting of acquired 
resistance in BRAF mutant CRC—including KRAS mutation or amplification, BRAF 
V600E amplification, and MAP2K1 mutation (30), thereby underscoring the likely 
importance of these specific mechanisms within the spectrum of acquired resistance 
in BRAF mutant CRC and supporting the likelihood that these specific alterations 
may be frequently observed in patients. This is also supported by the identification of 
two different genetic alterations identified at resistance to BRAF/MEK inhibition in 
plasma sample of a BRAF mutant CRC patient, i.e., the emergence of a KRAS 
mutation and a likely amplification of mutant BRAF V600E. In our resistant cell 
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models, KRAS alterations were the most common resistance mechanism. The high 
prevalence of KRAS mutations in CRC and its role in resistance to anti-EGFR 
therapies underpin a central role for KRAS in this disease. Analysis by standard 
sensitivity sequencing has typically identified KRAS and BRAF mutations in a 
mutually exclusive fashion in CRC (41-43). In order to explain these observations, it 
has been suggested that concomitant oncogenic activation of KRAS and BRAF 
would be counter-selected during tumorigenesis, as it would result in activation of 
cell-cycle inhibitory proteins of the Ink4/Arf locus, leading to oncogenic stress and 
senescence (44). Nevertheless, the use of more sensitive techniques, such as 
droplet digital PCR, have recently revealed that low-allele frequency KRAS 
mutations could coexist with BRAF V600E in CRC samples (7). These rare 
subclones may be present but might possess an unfavorable fitness compared to 
clones with only mutant BRAF. However, the selective pressure of BRAF-directed 
therapy may improve the proliferation rate of the double mutant clones while 
reducing the viability of cells bearing only mutant BRAF, thus driving outgrowth of 
resistant BRAF/KRAS double mutant clones. Indeed, a recent study analyzing tumor 
biopsies from BRAF mutant CRC patients obtained prior to BRAF-directed therapy 
revealed that more than 50% bear low frequency KRAS mutations (7). This finding 
might be explained by the 'Big Bang' model (45), whereby tumors grow 
predominantly as a single expansion producing numerous intermixed subclones, 
where the timing of an alteration rather than clonal selection for that alteration is the 
primary determinant of its pervasiveness. Similarly, it is possible that some of the 
other common acquired resistance mechanisms we have observed in BRAF mutant 
CRC, such as BRAF V600E amplification and MAP2K1 mutation, may also pre-exist 
in rare tumor subclones. Indeed, we previously found that rare tumor cells with BRAF 
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amplification could be identified in pre-treatment tumor biopsies from BRAF mutant 
CRC patients (32). Altogether, these observations suggest that KRAS as well as 
other resistance alterations could develop at an early stage of BRAF mutant 
colorectal tumorigenesis, thus laying the seeds for the eventual emergence of 
acquired resistance. In a resistant cell model and in our patient, BRAF combinatorial 
therapies have resulted in the appearance of at least two concomitant resistance 
mechanisms. Indeed, the lower percentage of KRAS mutant allele in comparison 
with to the TP53 founder mutation suggested that this variant may have been 
present in only a fraction of tumor cells distinct from the BRAF V600E amplified 
subset. These data are consistent with previous reports in melanomas resistant to 
BRAFi, either as monotherapy or in combination with MEKi, in which multiple 
resistance mechanisms have been described to co-occur in individual patients 
(46,47).  
 
The observation that all resistance mechanisms identified in our cell panel converge 
to reactivate MAPK signaling has important clinical implications. Since it may not be 
practical to design specific therapeutic strategies against each of the individual 
acquired resistance mechanisms observed in BRAF mutant CRC, there would be 
clear clinical advantages to developing a more “universal” therapeutic strategy 
targeting a common signalling output that would be capable of overcoming a 
spectrum of potential resistance mechanisms. By systematically comparing multiple 
drug combinations designed to achieve more optimal MAPK pathway suppression 
across the molecular landscape of acquired resistance mechanisms in BRAF mutant 
CRC, we were able to identify the most promising therapeutic candidates to 
overcome resistance. Although a few resistant cell lines showed only modest 
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sensitivity to these combinations, suggesting the possibility that these models might 
harbor additional MAPK-independent resistance mechanisms, overall we observed 
that the combination of BRAFi+EGFRi+MEKi or ERKi in combination with BRAFi 
and/or EGFRi displayed superior activity across the vast majority of resistant models. 
Therefore, these combinations may represent the most promising strategies for 
evaluation in clinical trials for patients with BRAF mutant CRC. Notably, the triple 
combination of BRAFi+EGFRi+MEKi is currently being evaluated in clinical trials, 
and preliminary results suggest improved response rate and progression-free 
survival compared to the individual doublet combinations (48), which is consistent 
with our findings, and suggests that improved activity against the common resistance 
mechanisms in BRAF mutant CRC may account in part for the improved clinical 
efficacy observed. 
 
Consistent with our findings, previously published reports have documented 
promising preclinical activity of ERK inhibition in BRAFi or MEKi resistant cell line 
models (27,38,39) and in MEKi+BRAFi and BRAFi+EGFRi resistant BRAF mutant 
CRC cells (30), supporting ERKi as key potential components of future clinical trial 
strategies for this disease. While it is likely that secondary mutations in ERK1/2 may 
limit the long-term efficacy of ERKi (49), it remains an important and unanswered 
question as to whether it is best to administer ERKi as monotherapy or whether ERKi 
might be more effective as part of drug combinations in BRAF mutant CRC. Indeed, 
it is possible that ERK inhibition alone might trigger survival-promoting feedback 
loops through alternative pathways that might be optimally suppressed with 
therapeutic combinations. In order to help guide future clinical trial strategies, our 
study begins to address this critical question, and suggests that ERKi appear to be 
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more effective against the spectrum of acquired resistance mutations in BRAF 
mutant CRC when administered in combination with BRAFi and/or EGFRi inhibitors. 
In fact, the triplet combination of ERKi+BRAFi+EGFRi appeared to be the most 
effective combination strategy overall across our panel of resistant cell line models. 
Thus, our study suggests that initial clinical trials of ERKi in BRAF mutant CRC 
patients should prioritize therapeutic combinations with BRAFi and EGFR inhibitors. 
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Table 1. Molecular alterations acquired upon resistance to targeted therapy 
combinations in BRAF mutant CRC cell lines.  
 
  
Drugs Cell line EGFR  KRAS NRAS MAP2K1 MAP2K2 BRAF  gene CNV 
D + T VACO432 WT WT WT L115P WT none  
V + S WiDr EGFR ampl. WT WT WT WT none 
E + C 
HROC87 WT G13D WT WT WT  none 
VACO432 WT A146T WT WT WT  none 
D + C 
VACO432 WT A146T WT WT WT  none 
WiDr WT KRAS ampl. WT WT WT  none 
V + C 
VACO432  
R.A WT G12D WT WT WT  none 
VACO432 
 R.B G465R  WT WT WT WT  none 
E + C + A VACO432 WT A146V A146T WT WT WT  none 
S + C 
HROC87 WT WT WT V211D WT  none 
WiDr WT WT WT WT WT 600E ampl.  
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Legend to Figures  
 
 
Figure 1. Generation of BRAF mutant CRC cells resistant to EGFR targeted 
agent and BRAF/MEK or PI3K inhibitors (A) Schematic representation of 
RAS/RAF/MEK and PI3K/AKT pathways. The orange boxes show the drugs used to 
generate resistant cell lines. List of the drug combinations used for generating 
resistant cell lines is shown on the right; all of these have been or are being 
evaluated in clinical trials. Drugs are abbreviated as follows: A=Alpelisib (PI3K 
inhibitor, PI3Ki); C= Cetuximab (EGFRi); D= Dabrafenib (BRAFi); E= Encorafenib 
(BRAFi); S= Selumetinib (MEKi); T= Trametinib (MEKi); V= Vemurafenib (BRAFi). 
(B) Parental and resistant cells were treated for 72 hours with the indicated molar 
drug concentrations. Cetuximab and alpelisib were given at a constant concentration 
of 5 µg/ml and 100 nM, respectively. In the vemurafenib and selumetinib 
combination, selumetinib was used at a constant concentration of 300 nM.  
 
Figure 2. Resistant cells maintain ERK1/2 phosphorylation after treatment. 
WiDr, VACO432 and HROC87 parental and resistant cells were treated with different 
drug combinations as indicated: cetuximab (C, 5 μg/ml); dabrafenib (D, 300 nM); 
encorafenib (E, 400 nM); alpelisib (A, 1 µM); vemurafenib (V, 2 µM); selumetinib (S, 
1 μM) and trametinib (T, 30 nM). Drug treatment was given for 5 hours prior to 
protein extraction.  
 
Figure 3. EGFR, KRAS and BRAF gene amplification confer acquired 
resistance to BRAF combination therapies. (A) Quantitative PCR for copy 
number evaluation of resistant cell lines in respect to their parental counterparts. 
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WiDr V+S, D+C and S+C resistant lines displayed gene amplification of EGFR, 
KRAS and BRAF, respectively. (B) FISH analysis on chromosome metaphase 
spreads confirmed gene amplification. Cell nuclei were colored by DAPI, FISH 
probes EGFR, KRAS, BRAF were labeled with texas red (red signal) and 
chromosome 7 (Chr7) and 12 (Chr12) with FITC (green signal). EGFR gene 
amplification was found extrachromosomally as double minutes, while a focal 
intrachromosomal amplification of KRAS and BRAF loci could be identified. 
  
Figure 4. EGFR amplification or ectodomain mutations play a causative role in 
acquired resistance to BRAF combination therapies. (A) Biochemical analyses of 
WiDr parental and V+S resistant cell lines, and of WiDr cells transduced with either 
GFP cDNA or EGFR WT cDNA. Cells were treated with vemurafenib and selumetinib 
before protein extraction. Actin was used as a loading control. (B) Effect of 
vemurafenib (at the indicated molar concentrations) in combination with selumetinib 
(0.5 µM) on the viability of WiDr cells transduced with EGFR WT cDNA. (C) Effect on 
cell viability of the addition of cetuximab to V+S treatment in WiDr resistant cells 
carrying EGFR amplification. Cells were treated with vemurafenib (1 µM), 
selumetinib (0.5 µM) or cetuximab alone or in their combinations. (D) EGFR and 
ERK expression and phosphorylation in VACO432 parental and resistant B cells, and 
in cells transduced with either GFP cDNA or EGFR G465R cDNA variants. VACO432 
cells were treated with vemurafenib and cetuximab for 5 hours before protein 
extraction. Vinculin was used as a loading control. (E) Effect of vemurafenib (at the 
indicated molar concentrations) in combination with cetuximab (5 µg/ml) on the 
viability of VACO432 cells transduced with EGFR G465R cDNA. (F) VACO432 with 
acquired EGFR G465R mutation upon treatment with vemurafenib and cetuximab 
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retain sensitivity to vemurafenib and gefitinib treatment. All survival data were 
assessed by ATP content measurement after 72 hours of treatment. Data are 
expressed as average ± s.d. of two independent experiments. 
 
Figure 5. Next generation sequencing of ctDNA of a BRAF mutant CRC patient 
at resistance to combined BRAF/MEK inhibition revealed an increase of BRAF 
V600E number of reads and the emergence of a KRAS G12C mutation. Data 
labels indicate number (#) of mutant reads over the total number of reads covering 
that position, detected by next generation sequencing in circulating tumor DNA 
(ctDNA) at baseline and resistance. PD, progressive disease. 
 
Figure 6. Acquired resistance to target therapy combinations can be overcome 
by vertical MAPK pathway suppression. The viability of parental and resistant cell 
lines treated with different drug combinations targeting EGFR, BRAF, MEK, ERK and 
PI3K was determined by ATP assay after 72 hours incubation. Relative survival was 
normalized to the untreated controls. Relative cell viability is depicted as indicated in 
the bottom color bar. Drugs were used at the concentrations listed in Supplementary 
Table S2. Results represent mean of at least two independent experiments, each 
performed in triplicate. 
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Supplementary Materials and Methods 
 
Cell lines 
WiDr, HROC87 and VACO432 cells were cultured at 37°C and 5% CO2 in RPMI 
1640, DMEM/F-12 and McCoy’s (Invitrogen), respectively, supplemented with 10% 
fetal bovine serum, 2 mM L-glutamine and antibiotics (100 U/ml penicillin and 100 
mg/ml streptomycin). Cell lines were tested and resulted negative for Mycoplasma 
contamination with the Venor GeM Classic Kit (Minerva Biolabs). 
 
Drugs and generation of drug resistant cells 
Vemurafenib, encorafenib, selumetinib and trametinib were purchased from Sequoia 
Chemicals; alpelisib and dabrafenib mesylate were from ChemieTek; gefitinib and 
SCH772984 were from Selleck Chemicals. The EGFR targeted monoclonal 
antibodies cetuximab and panitumumab were obtained from the Pharmacy at 
Ospedale Niguarda, Milan. Cetuximab was administered at a constant concentration 
of 5µg/ml, while vemurafenib, encorafenib, dabrafenib, selumetinib, and trametinib 
have been initially given at a concentration of 2 µM, 500 nM, 90 nM, 2 µM, 30 nM, 
respectively. The concentrations of chemical inhibitors were increased by discrete 
2 
 
intervals until reaching a final concentration at which the cells showed resistance 
(Table S1). 
 
Drug proliferation assays 
Cell proliferation experiments were carried out in 96-well plates in triplicate. Cells 
were plated (3,000 cells/well for VACO432 and WiDr, 4,000 cells/well for HROC87) 
in 100 µl complete growth medium. At 24 hours post-seeding, 100 µl of serum-free 
medium with or without cetuximab (5 μg/ml) was manually added to the cells. All 
other drugs were added directly on the plate by TECAN D300e digital dispenser 
(HP). After 72 hours’ treatment cell viability was assessed by ATP content using 
CellTiter-Glo Luminescent Assay (Promega). Viability was normalized as a 
percentage of control untreated cells. Data from growth-inhibition assays were 
plotted using the nonlinear regression curve fit modelling from GraphPad Prism-5 
(GraphPad Software). 
 
Western Blot analysis: drug treatments and antibodies 
Before biochemical analysis, cells were grown in their respective media devoid of 
drugs for four days and then treated for the times indicated in figure legends with 
cetuximab 5 μg/ml, alpelisib 1 μM, dabrafenib 300 nM, encorafenib 400 nM, 
vemurafenib 2 μM, selumetinib 1 μM, trametinib 30 nM, unless otherwise stated. 
Total cellular proteins was extracted by lysing cells in boiling Laemmli buffer (1% 
SDS, 50 mM Tris-HCl [pH 7.5], 150 mM NaCl) or in cold extraction buffer (50 mM 
HEPES [pH 7.4], 150 mM NaCl, 1% Triton-X-100, 10% glycerol, 5 mM EDTA, 2 mM 
EGTA; all reagents were from Sigma-Aldrich) in the presence of 1 mM sodium 
orthovanadate, 100 mM sodium fluoride and a mixture of protease inhibitors 
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(pepstatin, leupeptin, aprotinin, soybean trypsin inhibitor, and phenylmethylsulfonyl 
fluoride). The following primary antibodies were used (all from Cell Signaling 
Technology, except where otherwise indicated): anti-EGFR (clone13G8, Enzo Life 
Sciences; 1:100); anti-phospho EGFR (Tyr 1068; 1:1,000); anti-BRAF (Santa Cruz 
Biotechnology; 1:1,000); anti-pBRAF (Ser445; 1:1000); anti-BRAF V600E (Ventana 
1:500); anti-phospho-MEK1/2 (Ser217/221; 1:1,000); anti-MEK1/2 (1:1,000); anti-
phospho p44/42 ERK (Thr202/Tyr204; 1:1,000); anti-p44/42 ERK (1:1,000); anti-
phospho AKT (Ser473; 1:1,000); anti-AKT (1:1,000); HSP90 (Santa Cruz 
Biotechnology; 1:500); Actin (Santa Cruz Biotechnology; 1:1000); anti-vinculin 
(Millipore; 1:5,000). 
 
Fluorescence In Situ Hybridization 
FISH analyses on metaphase chromosomes and interphase nuclei were provided by 
the Division of Pathology, Ospedale Niguarda. Samples were fixed in a mixture of 
methanol and acetic acid and dehydrated at room temperature prior to probe 
hybridization. Probes and target DNA were co-denatured for 5 min at 75 °C and then 
hybridized overnight at 37 °C. Slides were washed with washing solution I (0.4x 
SSC, 0.3% NP-40) for 5 min at 73 °C, for 1 min with washing solution II (2x 
SSC/0.1% NP-40) at room temperature (Abnova) and finally counterstained with 4′,6-
diamidino-2-phenylindole (DAPI). FISH signals were evaluated with a Zeiss 
Axioscope Imager.Z1 (Zeiss) equipped with single and triple band pass filters. 
 
Cytotoxicity and cell cycle analysis assays  
For cell cycle flow cytometric analysis, VACO432 resistant cells were allowed to 
grow for 24 hours followed by 72 hours of treatment with SCH772984 alone or in 
4 
 
combination with dabrafenib and/or cetuximab. Drugs were used at the 
concentrations listed in Supplementary Table S2. Cells were fixed and stained with 
propidium iodide (DNA Con3 – CONSUL TS, Orbassano, Italy) overnight. All 
samples were acquired with the CyAn ADP (Beckman Coulter) and analyzed with 
FlowJo software (Tree Star).  
For cytotoxicity assays VACO432 resistant cells were seeded at 4,000 cells/well in 
96-well black optical-bottom plates (Nunc, Life Technologies). After 24 hours cells 
were treated with the same drug combinations and concentrations applied for cell 
cycle analysis. The CellTox Green cytotoxicity assay was performed according to 
manufacturer instructions and fluorescence was read by TECAN Spark 10M plate 
reader at 535 nm. As toxicity control, Lysis Solution was added (4 μl per 100 μl of 
cells) 30 minutes prior to reading. Subsequently, the amount of viable cells for each 
well was quantified by CellTiter-Glo Luminescent Assay (Promega). Background 
fluorescence (medium and CellTox Green dye) was subtracted and data were first 
normalized to the amount of cells and after to untreated control. 
 
Plasma processing and Next Generation Sequencing (NGS) analysis 
A minimum of 10 ml of whole blood was drawn in EDTA tubes before commencing 
treatment in September 2013 (baseline) and at radiological progression in March 
2014. Plasma was separated within 2 h through two different centrifugation steps 
(1,600g followed by 3,000g both centrifugations for 10 minutes at RT). PBMC were 
also obtained which served as a reference control for germ-line genomic DNA. 
Preparation of libraries was performed using up to 150 ng of plasma ctDNA and 100 
ng germ-line DNA obtained from PBMC. Germ-line gDNA was fragmented using 
transposons, adding simultaneously adapter sequences. For ctDNA libraries 
5 
 
preparation was used NEBNext® Ultra™ DNA Library Prep Kit for Illumina® (New 
England BioLabs Inc., Ipswich MA), with optimized protocol. Germ-line gDNA from 
PBMC after the tagmentation step, and ctDNA were used as template for 
subsequent PCR to introduce unique sample barcodes. Fragments’ size distribution 
of the DNA was assessed using the 2100 Bioanalyzer with a High Sensitivity DNA 
assay kit (Agilent Technologies, Santa Clara, CA). Equal amount of DNA libraries 
were pooled and subjected to targeted panel hybridization capture. Libraries were 
then sequenced using Illumina MiSeq sequencer (Illumina Inc., San Diego, CA, 
USA). 
 
Bioinformatics  
FastQ files generated by Illumina MiSeq sequencer were mapped to the human 
reference genome (assembly version hg19) using BWA-mem algorithm (1) SAMtools 
package (3) was used to sort aligned reads and to remove PCR duplicates. We used 
a custom script for NGS in order to call somatic variations when supported by at 
least 1.5% allelic frequency and 5% significance level obtained with a Fisher's Test, 
as previously described (2,3). Mutations were annotated by a custom pipeline 
printing out gene information, number of normal or mutated reads, the allelic 
frequencies and the variation effect (synonymous, nonsynonymous, stop-loss and 
gain). Each of these entries was associated with the corresponding number of 
occurrences in the COSMIC database (4). 
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Supplemental figure legends 
 
 
Supplementary Figure 1. Combinations of MEK inhibitor (selumetinib) or of BRAF 
inhibitor (vemurafenib) with EGFR inhibitor (cetuximab) display synergistic anti-
proliferative activity in BRAF mutant WiDr, VACO432 and HROC87 colorectal cancer 
cells. WiDr, VACO432 and HROC87 parental cells were treated with increasing 
concentration of selumetinib or vemurafenib with or without cetuximab (5 μg/ml). Cell 
viability was assayed after by an ATP assay. Data points represent the mean ± s.d. of two 
independent experiments, each performed in triplicate. 
 
Supplementary Figure 2. BRAF V600E amplification acquired in WiDr resistant to 
selumetinib and cetuximab, confers resistance to combination of MEK and EGFR 
inhibitors in CRC cells. (a) Digital PCR shows selective amplification of the BRAF V600E 
mutant allele in WiDr cells resistant to combined cetuximab and selumetinib. (b) 
Biochemical analysis on WiDr parental and resistant S+C was performed with the 
indicated antibodies. (c) Western blot analysis of proteins extracted from WiDr cells 5 days 
after transduction with a lentiviral vector expressing the hBRAF V600E cDNA. (d) WiDr-
BRAF V600E transduced cells displayed similar viability than the WiDr resistant cells upon 
treatment with MEK and EGFR inhibitors. Five days after transduction, cells were treated 
for 72 hours before viability was assessed by measuring ATP content. Data are expressed 
as average ± s.d. of two independent experiments, each performed in triplicate. 
 
Supplementary Figure 3. ERK inhibition induces cytotoxicity in VACO432 resistant 
to BRAF combination therapies. VACO432 resistant cell lines were cultured without 
drugs for four days and then treated for 72 hours with 185 nM ERKi, SCH772984, alone or 
in double or triple combination with 550 nM dabrafenib and/or 5 μg/ml cetuximab, after 
which cytotoxicity and cell cycle analysis were assesed.  (A) CellTox green cytoxicity 
assay was performed to identify cells with compromised membrane integrity characteristic 
of cell death. Data are expressed as fold change relative to DMSO treated control cells. 
Histograms and error bars indicate mean ± s.e.m of three independent experiments. (B) 
VACO432 resistant cell lines were analyzed for cell cycle and sub-G1 group by flow 
cytometry. Plots of cell number versus propidium iodide fluorescence intensity are shown. 
The percentage indicate the sub-G1 fraction.  
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Drug treatment Cell Line Final Drug concentration 
S + C 
HROC87 S 5 μM + C 5 μg/ml  
WiDr  S 5 μM + C 5 μg/ml  
D + C 
WiDr  D 5 μM + C 5 μg/ml  
VACO432 D 5 μM + C 5 μg/ml  
V + C 
VACO432 (R.A) V 5 μM + C 5 μg/ml  
VACO432 (R.B) V 3 μM + C 5 μg/ml  
E + C 
HROC87 E 2 μM + C 5 μg/ml  
VACO432 E 2 μM + C 5 μg/ml  
V + S WiDr  V 3 μM + S 1 μM 
D + T VACO432 D 0.25 μM + T 0.12 μM 
E + C + A VACO432 E 1 μM + C 5 μg/ml + B 0.5 μM 
Supplementary Table S1 
Supplementary table S1. List of drug concentrations at which cell lines were 
made resistant. 
Drugs Drug concentrations 
Encorafenib + Cetuximab E 550 nM + C 5 μg/ml 
Dabrafenib + Cetuximab D 550 nM + C 5 μg/ml 
Vemurafenib + Cetuximab V 1.1 μM + C 5 μg/ml 
Encorafenib + Cetuximab + Alpelisib E 550 nM + C 5 μg/ml + A 300 nM  
Selumetinib + Cetuximab S 1.1 μM + C 5 μg/ml 
Dabrafenib + Trametinib D 185 nM + T 30 nM 
Dabrafenib + Trametinib + Cetuximab D 185 nM + T 30 nM + C 5 μg/ml 
SCH772984 (ERKi) ERKi 185 nM 
SCH772984 (ERKi) + Cetuximab ERKi 185 nM +  C 5 μg/ml 
SCH772984 (ERKi) + Dabrafenib ERKi 185 nM +  D 550 nM 
SCH772984 (ERKi) + Dabrafenib + Cetuximab ERKi 185 nM +  D 550 nM +  C 5 μg/ml 
Supplementary Table S2 
Supplementary table 2. Drug concentrations applied in the cross-resistance 
combinatorial screening depicted in Figure 6. 
Primer name Sequence 
G
e
n
e
 C
o
p
y
 N
u
m
b
e
r 
HER2 gDNA FW TATGCAGGGCTGACGTAGTGC 
HER2 gDNA REV AATGTGTGCCACGAAACTGCT 
KRAS gDNA FW CTGAGCTCCCCAAATAGCTG 
KRAS gDNA REV AGGTTAGGGCTAGGCACCAT 
MET gDNA FW TGTTTTAAGATCTGGGCAGTG 
MET gDNA REV AATGTCACAACCCACTGAGG 
EGFR gDNA FW TCCAGGAGGTGGCTGGTTA 
EGFR gDNA REV CTAAGGCATAGGAATTTTCGTAGTACATATT 
BRAF gDNA FW GGGAAGTAAAGACAGGGAGGT 
BRAF gDNA REV AGAGAGGTAGGAAAGGGCAAG 
CHR12 gDNA FW GGGATCTTATGATGTGTCAGG 
CHR12 gDNA REV ACTCTTGGTCTCAGTCTGCC 
STS gDNA FW CCTTCAAGAGAAAGACGACAG 
STS gDNA REV AGGACTTATAAAAGGCAAGGG 
ULK2 gDNA FW TTTGTGTGTGTGACGGAGTCT 
ULK2 gDNA REV AGGCTAAGGCAGGAGAATGAG 
S
e
q
u
e
n
c
in
g
 
BRAF ex 15 FW TGCTTGCTCTGATAGGAAAATG 
BRAF ex 15 RV AGCATCTCAGGGCCAAAAAT 
KRAS ex 2 FW GGTGGAGTATTTGATAGTGTATTAACC 
KRAS ex 2 RV AGAATGGTCCTGCACCAGTAA 
KRAS ex 3 FW AAAGGTGCACTGTAATAATCCAGAC  
KRAS ex 3 RV ATGCATGGCATTAGCAAAGA 
KRAS ex 4 FW TGGACAGGTTTTGAAAGATATTTG 
KRAS ex 4 RV ATTAAGAAGCAATGCCCTCTCAAG 
NRAS ex 2 FW GTACTGTAGATGTGGCTCGC 
NRAS ex 2 RV AGAGACAGGATCAGGTCAGC 
NRAS ex 3 FW CTTATTTAACCTTGGCAATAGCA 
NRAS ex 3 RV GATTCAGAACACAAAGATCATCC 
EGFR ex 12 FW CCTCAAGGAGATAAGTGATGGAG  
EGFR ex 12 RV AAAGGACCCATTAGAACCAACTC 
MAP2K1 ex 2 FW TCCCGCGAAATTAATACGACTTGACTTGTGCTCCCCACTT 
MAP2K1 ex 2 RV GCTGGAGCTCTGCAGCTAAGGCAAACTCACCTTTCTGGC 
MAP2K1 ex 3 FW TCCCGCGAAATTAATACGACGTGCCAATGCCTGCCTTAGT 
MAP2K1 ex 3 RV GCTGGAGCTCTGCAGCTACCACCCAACTCTTAAGGCCA 
MAP2K1 ex 6 FW TCCCGCGAAATTAATACGACGCCTTGGTGTACAGTGTTTGC 
MAP2K1 ex 6 RV GCTGGAGCTCTGCAGCTAACATGTAGGACCTTGTGCCC 
MAP2K2 ex 2 FW TCCCGCGAAATTAATACGACAGGTAGCTAACCCCTACCCT 
MAP2K2 ex 2 RV GCTGGAGCTCTGCAGCTAAATCAGAATGCAGAGACCCG 
Supplementary Table S3 
Supplementary Table S3: List of primers for gene amplification and sequencing 
